The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial

Background Assessing genetic lifetime risk for prostate cancer has been proposed as a means of risk stratification to identify those for whom prostate-specific antigen (PSA) testing is likely to be most valuable. This project aimed to test the effect of introducing a genetic test for lifetime risk of prostate cancer in general practice on future PSA testing. Methods and findings We performed a cluster randomized controlled trial with randomization at the level of general practices (73 in each of two arms) in the Central Region (Region Midtjylland) of Denmark. In intervention practices, men were offered a genetic test (based on genotyping of 33 risk-associated single nucleotide polymorphisms) in addition to the standard PSA test that informed them about lifetime genetic risk of prostate cancer and distinguished between “normal” and “high” risk. The primary outcome was the proportion of men having a repeated PSA test within 2 years. A multilevel logistic regression model was used to test the association. After applying the exclusion criteria, 3,558 men were recruited in intervention practices, with 1,235 (34.7%) receiving the genetic test, and 4,242 men were recruited in control practices. Men with high genetic risk had a higher propensity for repeated PSA testing within 2 years than men with normal genetic risk (odds ratio [OR] = 8.94, p < 0.01). The study was conducted in routine practice and had some selection bias, which is evidenced by the relatively large proportion of younger and higher income participants taking the genetic test. Conclusions Providing general practitioners (GPs) with access to a genetic test to assess lifetime risk of prostate cancer did not reduce the overall number of future PSA tests. However, among men who had a genetic test, knowledge of genetic risk significantly influenced future PSA testing. Trial registration This study is registered with ClinicalTrials.gov, number NCT01739062.

[1]  K. D. Sørensen,et al.  Germline variation at 8q24 and prostate cancer risk in men of European ancestry , 2018, Nature Communications.

[2]  K. D. Sørensen,et al.  Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci , 2018, Nature Genetics.

[3]  Nawaid Usmani,et al.  Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants , 2018, Nature Communications.

[4]  I. Balslev,et al.  Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men , 2018, JAMA network open.

[5]  K. Pickles,et al.  General Practitioners’ Experiences of, and Responses to, Uncertainty in Prostate Cancer Screening: Insights from a Qualitative Study , 2016, PloS one.

[6]  Martin Eklund,et al.  Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. , 2015, The Lancet. Oncology.

[7]  J. Hugosson,et al.  Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. , 2015, European urology.

[8]  N. Lawrentschuk,et al.  Prostate cancer screening in Primary Health Care: the current state of affairs , 2015, SpringerPlus.

[9]  M. Borre,et al.  Variation in general practice prostate‐specific antigen testing and prostate cancer outcomes: An ecological study , 2015, International journal of cancer.

[10]  W. Lowrance,et al.  Prostate cancer risk prediction based on complete prostate cancer family history , 2014, The Prostate.

[11]  T. Tammela,et al.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.

[12]  Peter Kraft,et al.  A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer , 2014, Nature Genetics.

[13]  Henrik Toft Sørensen,et al.  The Danish Civil Registration System as a tool in epidemiology , 2014, European Journal of Epidemiology.

[14]  A. Edwards,et al.  A cluster-randomised, parallel group, controlled intervention study of genetic prostate cancer risk assessment and use of PSA tests in general practice—the ProCaRis study: study protocol , 2013, BMJ Open.

[15]  Peter Kraft,et al.  Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array , 2013, Nature Genetics.

[16]  V. Moyer,et al.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[17]  P. Glasziou,et al.  Optimal prostate-specific antigen screening interval for prostate cancer. , 2012 .

[18]  T. Fukui,et al.  Optimal prostate-specific antigen screening interval for prostate cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  G. Andriole,et al.  Risk-based prostate cancer screening. , 2012, European urology.

[20]  J. Søndergaard,et al.  General Practice and Primary Health Care in Denmark , 2012, The Journal of the American Board of Family Medicine.

[21]  Patrick Royston,et al.  Multiple Imputation by Chained Equations (MICE): Implementation in Stata , 2011 .

[22]  W. Shih,et al.  The impact of PSA testing frequency on prostate cancer incidence and treatment in older men , 2011, Prostate Cancer and Prostatic Diseases.

[23]  Martin Eklund,et al.  Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. , 2011, European urology.

[24]  Elsebeth Lynge,et al.  The Danish National Patient Register , 2011, Scandinavian journal of public health.

[25]  Vibeke Jensen,et al.  Danish education registers , 2011, Scandinavian journal of public health.

[26]  N. Schork,et al.  Effect of direct-to-consumer genomewide profiling to assess disease risk. , 2011, The New England journal of medicine.

[27]  D. Bowen,et al.  Do Men Make Informed Decisions about Prostate Cancer Screening? Baseline Results from the “Take the Wheel” Trial , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.

[28]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[29]  D. Neal.  PSA testing for prostate cancer improves survival--but can we do better? , 2010, The Lancet. Oncology.

[30]  A. D'Amico,et al.  American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 , 2010, CA: a cancer journal for clinicians.

[31]  Bjarne Lühr Hansen,et al.  Udredning og behandling af nedre urinvejssymptomer hos mænd og kvinder , 2009 .

[32]  V. Entwistle,et al.  Decision aids for people facing health treatment or screening decisions. , 2009, The Cochrane database of systematic reviews.

[33]  G. Aus,et al.  Prostate cancer , 2008, The Lancet.

[34]  Robert J Volk,et al.  Trials of decision aids for prostate cancer screening: a systematic review. , 2007, American journal of preventive medicine.

[35]  J. Emery,et al.  The GRAIDS Trial: a cluster randomised controlled trial of computer decision support for the management of familial cancer risk in primary care , 2007, British Journal of Cancer.

[36]  G. Elwyn,et al.  "It's a maybe test": men's experiences of prostate specific antigen testing in primary care. , 2007, The British journal of general practice : the journal of the Royal College of General Practitioners.

[37]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[38]  R. Thomson,et al.  Decision aids for people facing health treatment or screening decisions. , 2003, The Cochrane database of systematic reviews.

[39]  M. Barry.  Prostate-Specific–Antigen Testing for Early Diagnosis of Prostate Cancer , 2001 .

[40]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.